Foundation for Care of Neurological Illnesses, Greece
Athens, Attica, 11256, Greece
NCT Number: NCT04407819
The association of diabetes mellitus type 2 (T2DM) with sarcopenia has not been adequately investigated. Sarcopenia is characterized by progressive and generalized loss of skeletal muscle mass which may affect performance.
Looking for future studies?
Notify Me20 year–80 year
All sexes
Observational
Athens, Attica, 11256, Greece
The relationship between DM and sarcopenia has not been extensively investigated. Skeletal muscle is the primary site of glucose deposition, and decreased muscle mass plays a role in impaired glucose metabolism in patients with insulin resistance and type 2 diabetes. Skeletal muscle resistance to insulin action appears to be the link between type 2 diabetes (T2DM) and sarcopenia. Hyperglycemia is a metabolic dysfunction which can potentially damage muscle cells. Insulin deficiency leads to marked muscle catabolism that can be reversed by exogenous insulin administration.
The metabolic disorder in diabetics may be reversible.Thus, it may be possible to restore physical ability by restoring the musculoskeletal system.Therefore, the diagnosis of sarcopenia if made can lead to interventions which may prevent the deterioration of body composition and the subsequent deterioration of quality of life. According to the results of the aforementioned studies it is still inconclusive if the metabolic disorder in diabetes may be related to sarcopenia, or sarcopenia may be a consequence of diabetes.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
Time frame: Up to 12 weeks
Appendicular Muscle Mass/Height2
Time frame: Up to 12 weeks
percents in different groups
Time frame: Up to 12 weeks
percent of fat mass, Total Fat index
Dionyssiotis, Yannis, M.D.
Indiv
Acronym: SARCoDM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03118050
Aging, Atrophy
Galveston, Texas, United States
View Trial DetailsNCT07016958
Atrophy, Diabetes Mellitus
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03771417
Aging, Atrophy
Baton Rouge, Louisiana, United States
View Trial DetailsNCT05389566
Atrophy, Autonomic Neuropathy, Diabetic
Aalborg, Denmark
View Trial Details